The Correlation Between Novel Survival-related Alternative Splicing Signature and Prognostic Prediction and Immune Microenvironment in Clear Cell Renal Cell Carcinoma
暂无分享,去创建一个
G. Wang | Wen-Gang Jian | Yi-peng Yu | W. Xue | Z. Xia | Li-Cheng Cai | Yong-jiang Yu | Teng-da Wang | Yu-yang Meng | W. Yao | Cheng Zhang | Wengang Jian | Tengda Wang | Cheng Zhang
[1] Gong Yang,et al. Extracellular matrix protein-1 secretory isoform promotes ovarian cancer through increasing alternative mRNA splicing and stemness , 2021, Nature Communications.
[2] Yuan Zhang,et al. The landscape and biological relevance of aberrant alternative splicing events in esophageal squamous cell carcinoma , 2021, Oncogene.
[3] Xiaobing Jiang,et al. Identification and Validation of a Prognostic Immune-Related Alternative Splicing Events Signature for Glioma , 2021, Frontiers in Oncology.
[4] Chuan Liu,et al. Identification of Tumor Microenvironment-Related Alternative Splicing Events to Predict the Prognosis of Endometrial Cancer , 2021, Frontiers in Oncology.
[5] B. Yu,et al. Alternative Splicing Events in Tumor Immune Infiltration in Colorectal Cancer , 2021, Frontiers in Oncology.
[6] Mugen Liu,et al. Comprehensive characterization of alternative splicing in renal cell carcinoma , 2021, Briefings Bioinform..
[7] M. Stern,et al. Splicing patterns in SF3B1 mutated uveal melanoma generate shared immunogenic tumor-specific neo-epitopes. , 2021, Cancer Discovery.
[8] Hao Xu,et al. Immunological significance of prognostic alternative splicing signature in hepatocellular carcinoma , 2021, Cancer cell international.
[9] Steven L. Chang,et al. Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma , 2021, Cancer cell.
[10] Steven L. Chang,et al. Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. , 2021, Cancer cell.
[11] R. Rabadán,et al. Computing the Role of Alternative Splicing in Cancer. , 2021, Trends in cancer.
[12] E. V. Van Allen,et al. Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma , 2021, Nature Reviews Clinical Oncology.
[13] Yingwei Xue,et al. The landscape of alternative splicing reveals novel events associated with tumorigenesis and the immune microenvironment in gastric cancer. , 2021, Aging.
[14] W. Rathmell,et al. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality , 2020, Nature Reviews Nephrology.
[15] E. Giovannetti,et al. The role of alternative splicing in cancer: From oncogenesis to drug resistance. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[16] Lin Zhu,et al. Identification of Novel Alternative Splicing Events Associated With Tumorigenesis, Protein Modification, and Immune Microenvironment in Early-Onset Gastric Cancer , 2020, bioRxiv.
[17] Fan Lin,et al. Comprehensive analysis and establishment of a prediction model of alternative splicing events reveal the prognostic predictor and immune microenvironment signatures in triple negative breast cancer , 2020, Journal of Translational Medicine.
[18] Z. Ye,et al. HnRNP A1 - mediated alternative splicing of CCDC50 contributes to cancer progression of clear cell renal cell carcinoma via ZNF395 , 2020, Journal of Experimental & Clinical Cancer Research.
[19] G. Narla,et al. Splice of Life for Cancer: Missplicing of PPP2R5A by Mutant SF3B1 Leads to MYC Stabilization and Tumorigenesis. , 2020, Cancer discovery.
[20] J. Valcárcel,et al. Roles and mechanisms of alternative splicing in cancer — implications for care , 2020, Nature Reviews Clinical Oncology.
[21] L. Pasqualucci,et al. Mutations in the RNA splicing factor SF3B1 promote tumorigenesis through MYC stabilization. , 2020, Cancer discovery.
[22] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[23] Xianxin Li,et al. Systematic analysis of survival‐associated alternative splicing signatures in clear cell renal cell carcinoma , 2019, Journal of cellular biochemistry.
[24] Jing Huang,et al. Survival-Associated Alternative Splicing Events in Pan-Renal Cell Carcinoma , 2019, Front. Oncol..
[25] J. Nielsen,et al. Classification of clear cell renal cell carcinoma based on PKM alternative splicing , 2019, bioRxiv.
[26] Jun Ma,et al. Comprehensive characterization of the alternative splicing landscape in head and neck squamous cell carcinoma reveals novel events associated with tumorigenesis and the immune microenvironment , 2019, Theranostics.
[27] D. Baltimore,et al. Alternative mRNA splicing in cancer immunotherapy , 2019, Nature Reviews Immunology.
[28] F. Liu,et al. HnRNPL promotes Wilms tumor progression by regulating the p53 and Bcl2 pathways , 2019, OncoTargets and therapy.
[29] Jiaming Su,et al. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma , 2019, Journal of cellular physiology.
[30] H. Kume,et al. Discovery of Functional Alternatively Spliced PKM Transcripts in Human Cancers , 2019, bioRxiv.
[31] Angela N. Brooks,et al. A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion. , 2019, Cancer cell.
[32] R. May,et al. Alternative splice variants of DCLK1 mark cancer stem cells, promote self‐renewal and drug‐resistance, and can be targeted to inhibit tumorigenesis in kidney cancer , 2018, International journal of cancer.
[33] Jun Luo,et al. Alternative splicing in prostate cancer , 2018, Nature Reviews Clinical Oncology.
[34] Steven J. M. Jones,et al. Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients , 2018, Cancer cell.
[35] L. Zender,et al. PTBP1-Mediated Alternative Splicing Regulates the Inflammatory Secretome and the Pro-tumorigenic Effects of Senescent Cells , 2018, Cancer cell.
[36] Zoltan Szallasi,et al. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal , 2018, Cell.
[37] Ping Zhu,et al. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types. , 2018, Cell reports.
[38] B. Rini,et al. Treatment of renal cell carcinoma: Current status and future directions , 2017, CA: a cancer journal for clinicians.
[39] F. Baralle,et al. Alternative splicing as a regulator of development and tissue identity , 2017, Nature Reviews Molecular Cell Biology.
[40] C. Duan,et al. Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM. , 2017, American journal of cancer research.
[41] Qihong Huang,et al. Alternative Splicing of EZH2 pre-mRNA by SF3B3 Contributes to the Tumorigenic Potential of Renal Cancer , 2016, Clinical Cancer Research.
[42] P. A. van den Brandt,et al. A Four-Gene Promoter Methylation Marker Panel Consisting of GREM1, NEURL, LAD1, and NEFH Predicts Survival of Clear Cell Renal Cell Cancer Patients , 2016, Clinical Cancer Research.
[43] Gianluca Bontempi,et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data , 2015, Nucleic acids research.
[44] Robert Brown,et al. TCGASpliceSeq a compendium of alternative mRNA splicing in cancer , 2015, Nucleic Acids Res..
[45] David Allman,et al. Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy. , 2015, Cancer discovery.
[46] IRF-1 regulates alternative mRNA splicing of carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) in breast epithelial cells generating an immunoreceptor tyrosine-based inhibition motif (ITIM) containing isoform , 2014, Molecular Cancer.
[47] Jian Zhang,et al. Misregulation of pre-mRNA alternative splicing in cancer. , 2013, Cancer discovery.
[48] Z. Szallasi,et al. Prognostic and predictive markers in metastatic renal cell carcinoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[49] Han Yong Choi,et al. The epidemiology of renal cell carcinoma. , 2011, European urology.